scholarly journals Genetic polymorphisms of ACE1 , ACE2 , and TMPRSS2 associated with COVID‐19 severity: A systematic review with meta‐analysis

2022 ◽  
Author(s):  
Wacharapol Saengsiwaritt ◽  
Jiraphun Jittikoon ◽  
Usa Chaikledkaew ◽  
Wanvisa Udomsinprasert
Keyword(s):  
Systematic Review ◽  
Genetic Polymorphisms ◽  
Meta Analysis

scholarly journals Association of the genetic polymorphisms in inhibiting and activating molecules of immune system with rheumatoid arthritis: A systematic review and meta-analysis

2021 ◽  
Vol 26 (1) ◽  
pp. 22
Author(s):  
Nima Rezaei ◽  
MohammadJavad Mousavi ◽  
MohammadReza Hooshangi Shayesteh ◽  
Sirous Jamalzehi ◽  
Reza Alimohammadi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Immune System ◽  
Genetic Polymorphisms ◽  
Meta Analysis

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis

2014 ◽  
Vol 15 (13) ◽  
pp. 1687-1700 ◽  
Author(s):  
Daniel E Jonas ◽  
Halle R Amick ◽  
Cynthia Feltner ◽  
Roberta Wines ◽  
Ellen Shanahan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alcohol Use ◽  
Genetic Polymorphisms ◽  
Meta Analysis ◽  
Alcohol Use Disorders

Human papillomavirus and host genetic polymorphisms in carcinogenesis: A systematic review and meta-analysis

2014 ◽  
Vol 61 (2) ◽  
pp. 220-229 ◽  
Author(s):  
Steven Habbous ◽  
Vincent Pang ◽  
Wei Xu ◽  
Eitan Amir ◽  
Geoffrey Liu
Keyword(s):  
Systematic Review ◽  
Human Papillomavirus ◽  
Genetic Polymorphisms ◽  
Meta Analysis ◽  
Host Genetic

scholarly journals Association between Genetic Polymorphisms in Interleukin Genes and Recurrent Pregnancy Loss – A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0169891 ◽  
Author(s):  
Meixiang Zhang ◽  
Jiawei Xu ◽  
Xiao Bao ◽  
Wenbin Niu ◽  
Linlin Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Genetic Polymorphisms ◽  
Pregnancy Loss ◽  
Recurrent Pregnancy Loss ◽  
Meta Analysis

scholarly journals Genetic polymorphisms of non-coding RNAs associated with increased head and neck cancer susceptibility: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 62508-62523 ◽  
Author(s):  
Weiyi Pan ◽  
Chenzhou Wu ◽  
Zhifei Su ◽  
Zexi Duan ◽  
Longjiang Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Genetic Polymorphisms ◽  
Neck Cancer ◽  
Cancer Susceptibility ◽  
Meta Analysis ◽  
Non Coding Rnas

scholarly journals Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e027940 ◽  
Author(s):  
Seungwon Yang ◽  
Se Jung Hwang ◽  
Jung Yun Park ◽  
Eun Kyoung Chung ◽  
Jangik I Lee
Keyword(s):  
Systematic Review ◽  
Liver Injury ◽  
Genetic Polymorphisms ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Organic Anion ◽  
Close Monitoring ◽  
Drug Induced ◽  
Slow Acetylator ◽  
Drug Induced Liver Injury

ObjectivesThe objective of this study was to investigate the association between genetic polymorphisms of N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), glutathione S-transferase (GST) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) and the risk of anti-tuberculosis drug-induced liver injury (ATDILI).DesignSystematic review and meta-analysis.Data sourcesPubMed, Embase, Web of Science and Cochrane Reviews databases were searched through April 2019.Eligibility criteriaWe included case-control or cohort studies investigating an association between NAT2, CYP2E1, GST or SLCO1B1 polymorphisms and the ATDILI risk in patients with tuberculosis.Data extraction and synthesisThree authors screened articles, extracted data and assessed study quality. The strength of association was evaluated for each gene using the pooled OR with a 95% CI based on the fixed-effects or random-effects model. Sensitivity analysis was performed to confirm the reliability and robustness of the results.ResultsFifty-four studies were included in this analysis (n=26 for CYP2E1, n=35 for NAT2, n=19 for GST, n=4 for SLCO1B1). The risk of ATDILI was significantly increased with the following genotypes: CYP2E1 RsaI/PstI c1/c1 (OR=1.39, 95% CI 1.06 to 1.83), NAT2 slow acetylator (OR=3.30, 95% CI 2.65 to 4.11) and GSTM1 null (OR=1.30, 95% CI 1.12 to 1.52). No significant association with ATDILI was found for the genetic polymorphisms of CYP2E1 DraI, GSTT1, GSTM1/GSTT1, SLCO1B1 388A>G and SLCO1B1 521T>C (p>0.05).ConclusionsATDILI is more likely to occur in patients with NAT2 slow acetylator genotype, CYP2E1 RsaI/PstI c1/c1 genotype and GSTM1 null genotype. Close monitoring may be warranted for patients with these genotypes.

Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 20 (4) ◽  
pp. 266-274 ◽  
Author(s):  
Shuang Zhou ◽  
Qian Xiang ◽  
Guangyan Mu ◽  
Lingyue Ma ◽  
Shuqing Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Blood Glucose ◽  
Genetic Polymorphisms ◽  
Blood Glucose Concentration ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
Current Systematic Review ◽  
Potential Impact ◽  
Reported Data ◽  
Insufficient Number

Objective: The purpose of this systematic review and meta-analysis was to summarize the potential impact of CYP2C8 and SLCO1B1 genetic polymorphisms on repaglinide pharmacokinetics. Methods: A systematic search was conducted using electronic databases. Eligible studies reported data from pharmacokinetic evaluations of repaglinide in healthy adults according to different categories of CYP2C8 and SLCO1B1 genetic polymorphisms. Results: Six studies including a total of 191 participants met the inclusion criteria. We noted that CYP2C8 *1/*3 carriers exhibited lower AUC(0-∞) (SMD: -0.77; 95%CI: -1.23 to -0.30; P=0.001) and Cmax (SMD: -0.94; 95%CI: - 1.41 to -0.47; P<0.001) than CYP2C8 *1/*1 carriers. There were no significant differences in AUC(0-∞), Cmax, t1/2 and mean change in blood glucose concentration between *1/*4 and *1/*1 carriers. Further, *3/*3 carriers had lower Cmax (SMD: -1.42; 95%CI: -2.66 to -0.17; P=0.026) than *1/*1 carriers. Additionally, *3/*3 carriers had lower Cmax than *1/*3 carriers (SMD: -1.20; 95%CI: -2.40 to -0.00; P=0.050). Finally, we noted that repaglinide pharmacokinetics did not differ by SLCO1B1 genotype. Conclusion: The current systematic review and meta-analysis indicated that the genotype of CYP2C8, but not SLCO1B1, may affect repaglinide pharmacokinetics. However, because of the comparatively insufficient number of published studies included, our conclusions require support from additional studies.

scholarly journals NR1I2 genetic polymorphisms and the risk of anti‐tuberculosis drug‐induced hepatotoxicity: A systematic review and meta‐analysis

2020 ◽  
Vol 8 (6) ◽  
Author(s):  
Miaomiao Yang ◽  
Yunliang Qiu ◽  
Yanyu Jin ◽  
Wenpei Liu ◽  
Qingliang Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Genetic Polymorphisms ◽  
Meta Analysis ◽  
Drug Induced
Sign in / Sign up

Export Citation Format

Share Document